Leap Therapeutics, Inc.

Historical 13F Holders

Symbol
CYPH
CUSIP
52187K200
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 52187K200 since 12/18/2024, newest first.

Filer % of Class Filed
Winklevoss Capital Fund, LLC 13D/A Amendment 2
19.9% 8/19/2026
Event 8/17/2026
Gilead Sciences, Inc. 13G/A Amendment 1 0% 2/12/2026
Event 12/31/2025
Winklevoss Capital Fund, LLC 13D/A Amendment 1
19.9% 11/21/2025
Event 10/8/2025
Severns Sean Michael 13G 10.6% 11/18/2025
Event 11/12/2025
Winklevoss Capital Fund, LLC 13D
19.9% 10/16/2025
Event 10/8/2025
Samsara BioCapital, L.P. 13G/A Amendment 1
0% 8/14/2025
Event 6/30/2025
Balyasny Asset Management L.P. 13G/A Amendment 1
0% 2/14/2025
Event 12/31/2024
BeiGene, Ltd. 13D/A Amendment 2 0% 10/31/2024
Event 10/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 163 k $543 k
2026 Q2 55 14.9 M $9.13 M
2026 Q1 47 7.32 M $5.94 M
2025 Q4 44 8.67 M $10.1 M
2025 Q3 37 12.7 M $5.76 M
2025 Q2 47 13.8 M $4.08 M
2025 Q1 49 16.7 M $5.09 M
2024 Q4 61 19.2 M $55.3 M
2024 Q3 53 14.8 M $38.1 M
2024 Q2 51 14.7 M $28.9 M
2024 Q1 50 8.47 M $22.5 M
2023 Q4 51 6.87 M $28.5 M
2023 Q3 46 7.74 M $10.6 M
2023 Q2 41 7.71 M $24.1 M